Kouryu Kyoju

Main Menu

  • Home
  • Japan institute
  • Japanese foundation
  • Japan government
  • Japan company
  • Japanese currency

Kouryu Kyoju

Header Banner

Kouryu Kyoju

  • Home
  • Japan institute
  • Japanese foundation
  • Japan government
  • Japan company
  • Japanese currency
Japan company
Home›Japan company›Oligomerix Announces Key Organizational Changes as Part of the Transition to a Clinically Focused Company

Oligomerix Announces Key Organizational Changes as Part of the Transition to a Clinically Focused Company

By Jane R. Chase
July 20, 2022
0
0

WHITE PLAINS, NY–(BUSINESS WIRE)–Oligomerix, Inc., a private company pioneering the development of tau-targeting small molecule therapeutics for rare neurodegenerative diseases and Alzheimer’s disease, today announced several organizational changes reflecting the transition to a stage-stage pharmaceutical company. clinical.

Oligomerix will now operate as two separate business units: 1) Discovery Group and 2) Development Group, which will include both clinical and commercial development activities. As part of this reorganization, William Erhardt, MD, formerly Chief Medical Officer of Oligomerix, will become President, Head of Development and Operations.

Dr. Erhardt’s primary focus will be to lead the organization in the clinic and take on all the duties and responsibilities of this task for the entire organization. Dr. Moe will remain Chief Executive Officer and will assume the new responsibility of leading the Discovery Group as Head of Research and Strategy, and working in conjunction with Eliot Davidowitz, Ph.D., Chief Scientific Officer of Oligomerix. In addition, Robert Foerster, Chief Financial Officer, assumes the additional role of Chief Operating Officer in recognition of his very significant contributions to Oligomerix.

“Oligomerix continues to make significant progress with our oral small molecule tau self-association inhibitor, and this revamp is an important step toward clinical testing,” said Dr. Moe. “We are extremely fortunate to have Bill’s many years of pharmaceutical and clinical experience leading programs like ours successfully in and through development. In the additional role of COO, Bob Foerster’s biopharmaceutical and financial experience will ensure that our operational strategies stay on track as we begin first-in-human studies later this year.

With over 20 years of executive leadership experience in the biopharmaceutical industry, Dr. Erhardt joined Oligomerix last year as Chief Medical Officer. Prior to joining Oligomerix, he was Senior Vice President, Head of Clinical Development and Operations at Pfizer, Inc., responsible for Pfizer’s clinical development operations globally, and leading a team of more than 25,000 Pfizer researchers. During his long tenure at Pfizer, Bill was responsible for overseeing multiple clinical development and medical affairs units across multiple therapeutic areas, including Pfizer’s Phase I units.

“I am very pleased to assume the role of President, Head of Development and Operations of Oligomerix as we transition from discovery research to a clinically focused biopharmaceutical company. There is a critical unmet need for innovative approaches to treat Alzheimer’s disease and other rare neurodegenerative disorders, and I believe our pioneering therapy can have a significant impact in this area,” said Dr. Erhardt.

Mr. Foerster is a seasoned pharmaceutical executive with experience in many financial, therapeutic and functional areas during his 28 years at Pfizer. His roles included that of Senior Director

Business Development for Emerging Markets, Senior Business Development Manager – Japan, where he was responsible for the entire development portfolio, numerous business alliances, strategic planning and was a member of the management team. He was Director/Team Leader – Neuroscience for New Product Development and Director of Financial Operations for the Africa Middle East region. Mr. Foerster holds a BA in Economics from Dartmouth and an MBA in Finance from Rutgers.

In June, Oligomerix announced a $2.7 million Series B expansion raise to support Phase 1 clinical development.

About the Oligomerix Lead Program

Oligomerix’s lead clinical candidate is an oral small molecule tau self-association inhibitor that targets the onset of the tau aggregation cascade, a process thought to be important in the development of Alzheimer’s disease and other neurodegenerative disorders. The lead candidate has demonstrated efficacy in animal models of tau-mediated neurodegeneration. Preclinical safety studies have been completed and phase 1a clinical studies are expected to begin this year.

About Oligomerix, Inc.

Oligomerix is ​​an emerging clinical-stage biotechnology company focused on the development of disease-modifying therapies for neurodegenerative diseases characterized by aberrant tau protein ranging from rare tauopathies such as progressive supranuclear palsy and frontotemporal dementia to Alzheimer’s disease. Alzheimer’s.

Oligomerix discovers and develops differentiated, oral, small molecule inhibitors of tau self-association that are easy to administer and cost effective. Oligomerix’s portfolio of compounds is expected to provide a potentially lower cost treatment alternative and/or complement to new emerging high cost therapeutic options such as monoclonal antibody products.

Oligomerix is ​​headquartered at Westchester Park Center in White Plains, New York and has laboratory facilities at the Ullmann Research Center for Health Sciences within the Albert Einstein College of Medicine. Follow Oligomerix on Twitter and LinkedIn.

Oligomerix is ​​seeking strategic partners and investors to support the acceleration and advancement of these important programs. For more information about Oligomerix, please visit our new website at https://oligomerix.com/.

Related posts:

  1. Familiar faces dominate the boards of Japanese companies
  2. Japan: Company Builds Robot to Help Elderly Staff | Science and technology news
  3. Japanese company presidents prefer to live near work: Akasaka tops most popular areas
  4. Japanese company accused of trying to export drone engine to China

Categories

  • Japan company
  • Japan government
  • Japan institute
  • Japanese currency
  • Japanese foundation

Recent Posts

  • Kevin Durant Charity Foundation unveils first basketball court in Tokyo
  • Asahi Kasei collaborated with the Akshaya Patra Foundation to launch the CSR initiative “Solving Hunger with Asahi Kasei”
  • The Right Automotive Company – CleanTechnica
  • US and Synergeia Foundation Train Filipino Educators in Early Childhood Literacy
  • Medical Electrodes Market 2022 | Top Companies Revenue, Share, In-Depth Industry Analysis, Size, Emerging Trends, Challenges, Competitive Landscape, Regional Analysis, Forecast to 2028

Archives

  • August 2022
  • July 2022
  • June 2022
  • May 2022
  • April 2022
  • March 2022
  • February 2022
  • January 2022
  • December 2021
  • November 2021
  • October 2021
  • September 2021
  • August 2021
  • July 2021
  • June 2021
  • May 2021
  • April 2021
  • March 2021
  • February 2021
  • January 2021
  • December 2020
  • November 2020
  • October 2020
  • September 2020
  • August 2020
  • July 2020
  • April 2020
  • March 2020
  • February 2020
  • January 2020
  • December 2019
  • September 2019
  • June 2019
  • May 2019
  • April 2019
  • February 2019
  • December 2018
  • November 2018
  • October 2018
  • September 2018
  • August 2018
  • July 2018
  • June 2018
  • May 2018
  • April 2018
  • March 2018
  • January 2018
  • May 2017
  • April 2017
  • February 2017
  • December 2016
  • September 2016
  • August 2016
  • April 2016
  • March 2016
  • February 2016
  • November 2015
  • August 2015
  • January 2015
  • April 2014
  • October 2012
  • April 2011
  • March 2011
  • November 2010
  • September 2009
  • Privacy Policy
  • Terms and Conditions